#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cutaneous T-cell lymphoma refractory Immunodeficiency congenital Shprintzen-Goldberg syndrome Pouchitis Neurodegenerative disorder Acute leukaemia Non-Hodgkin's lymphoma Plasma cell myeloma Epstein-Barr virus associated lymphoproliferative disorder Ocular lymphoma Immune thrombocytopenia Adrenoleukodystrophy T-cell lymphoma Thromboangiitis obliterans Small intestine leiomyosarcoma More trials…

    Learn about Rare Diseases

    Tuberous sclerosis complex – Diagnostics Lymphatic malformation Gaucher’s disease type III – Basic Information Angiosarcoma recurrent – Basic Information Erdheim-Chester disease – Treatment Cystic fibrosis – Diagnostics Systemic sclerosis pulmonary – Life with Disease Lymphatic malformation – Trials in Disease Factor IX deficiency – Life with Disease Undifferentiated sarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Triptorelin Pamoate Munc-Cd34 Sodium Iotalamate (125I) Mk-0482 SAR444336 Pitavastatin Calcium Ro7269162 Paracetamol Dalbavancin Almagate Enmetazobactam Pembrolizumab Ferric Carboxymaltose Rosnilimab AZD5148 Motixafortide Sumatriptan Succinate Napabucasin Thiocolchicoside Ulonivirine More therapies…

    Learn about Your Condition

    Nervous system disorder Epicondylitis Bartonellosis Lung neoplasm malignant Tissue anoxia Polycythaemia vera Procedural headache Anal squamous cell carcinoma Oesophagogastroscopy Gastric cancer Bacteraemia Diverticulitis Magnetic resonance imaging CADASIL Leukoencephalopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Epirubicin
    • Exemestane
    Belgium France Greece Ireland Italy Poland +1

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Patritumab Deruxtecan
    • Capecitabine
    France Germany Greece Hungary Italy Poland +1

  • Preoperative Elacestrant and PULSAR Adaptive Radiotherapy for Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Study for Patients with Stage II-III Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Italy

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal

  • Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Epirubicin Hydrochloride
    • Capecitabine
    Spain

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Elacestrant
    • Anastrozole
    • Exemestane
    Austria Belgium Czechia Denmark Finland France +9
Previous Page
1 2 3 4 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!